Thymosin Alpha-1

1. Overview

Thymosin alpha-1 (Ta1), also known by its pharmaceutical name thymalfasin and marketed as Zadaxin, is a 28-amino acid immunomodulatory peptide originally isolated from the thymus gland [1]. It was first characterized in 1972 by Allan L. Goldstein and colleagues at the University of Texas Medical Branch (Galveston) as part of a broader effort to identify the biologically active components of "thymosin fraction 5," a partially purified extract of calf thymus that could restore immune function in thymectomized animal models [1][15]. The peptide was sequenced and synthesized by 1977, making it one of the first thymic peptides available for clinical investigation [1].

Ta1 is a naturally occurring peptide produced in the thymus by cleavage of the precursor protein prothymosin alpha (ProTa), a 113-amino acid nuclear protein. The mature Ta1 peptide consists of 28 amino acid residues with an acetylated N-terminus (N-alpha-acetylserine) and a molecular weight of approximately 3,108 Da. Its primary sequence is: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn [1][12][24].

The peptide has been approved for clinical use as an immunomodulator in over 35 countries including China, Italy, India, South Korea, the Philippines, and multiple countries in South America, the Middle East, and Southeast Asia [15][16]. It is primarily approved for the treatment of chronic hepatitis B and as an immune-enhancing adjunct. Notably, thymosin alpha-1 has not received approval from the U.S. Food and Drug Administration or the European Medicines Agency. In 2023, the FDA placed additional restrictions on its compounding status in the United States [28].

The clinical development program has been extensive, spanning hepatitis B, hepatitis C, HIV/AIDS, cancer immunotherapy, sepsis, vaccine enhancement, and most recently COVID-19. A comprehensive 2024 review documented evidence from over 30 clinical trials involving more than 11,000 human subjects [28].

Molecular Weight

3108 Da (28 amino acids)

Sequence

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN

Half-life

~2 hours (subcutaneous)

Standard Dose

1.6 mg SC twice weekly

Routes Studied

Subcutaneous injection

FDA Status

Not approved. Approved in 35+ countries (as Zadaxin).

2. Mechanism of Action

Thymosin alpha-1 functions as a biological response modifier that acts on both the innate and adaptive arms of the immune system. Unlike conventional cytokines, it does not directly stimulate immune cells in an antigen-specific manner but rather modulates and optimizes immune responses through several interconnected pathways [12][13][24].

Toll-Like Receptor Signaling

A central mechanism of Ta1 involves direct interaction with Toll-like receptors (TLRs) on immune cells. Research has demonstrated that Ta1 binds to TLR2, TLR3, TLR4, TLR7, and TLR9 on both myeloid and plasmacytoid dendritic cells [12][13]. Upon TLR engagement, Ta1 activates downstream signaling cascades including:

• TLR3/4/9 → IRF3 and NF-kB pathways: Promoting proliferation and activation of target immune cells [12]
• TLR2 → NF-kB and p38 MAPK pathways: Modulating inflammatory responses [12]
• TLR7 → MyD88 signaling pathway: Enhancing antiviral innate immunity [12]

Importantly, the effects are context-dependent. Giacomini et al. (2015) demonstrated that Ta1 enhances immune responses to viral stimuli (via TLR3/7/8 agonists) while paradoxically suppressing responses to bacterial stimuli (via TLR2/4). This dual effect — amplifying antiviral immunity while dampening excessive bacterial inflammation — may explain its clinical utility in both chronic viral infections and hyperinflammatory conditions such as sepsis [11].

Dendritic Cell Maturation and Activation

Yao et al. (2007) showed that Ta1 promotes the differentiation and functional maturation of dendritic cells (DCs) from peripheral blood CD14+ monocytes. Treatment with Ta1 resulted in rapid activation of p38 MAPK and NF-kB in immature DCs, significant upregulation of surface markers CD40, CD80, and MHC class I/II molecules, approximately 30% reduction in antigen uptake (indicating functional shift from capture to presentation), and enhanced capacity to stimulate allogeneic T-cell proliferation in mixed lymphocyte reactions [10].

T-Cell Differentiation and Activation

Ta1 promotes the maturation and differentiation of T lymphocytes, particularly:

• CD4+ T-helper cells: Ta1 shifts the Th1/Th2 balance, generally favoring Th1 responses (interferon-gamma, IL-2 production) in the context of chronic viral infections [13]
• CD8+ cytotoxic T cells: Enhanced cytotoxic T-lymphocyte activity has been observed in multiple clinical settings [21]
• Regulatory T cells (Tregs): In sepsis models, Ta1 promoted apoptosis of suppressive Tregs, potentially releasing the immune system from excessive immunosuppression [6]

Ta1 increases IL-2 production and IL-2 receptor expression on normal mitogen-stimulated T cells [29]. It also stimulates interferon-alpha and interferon-gamma production [13][27].

Natural Killer Cell Enhancement

Ta1 enhances NK cell cytotoxic activity, both directly and synergistically with interferon-alpha and IL-2. Garaci et al. (1994) demonstrated that the combination of Ta1 with zidovudine and interferon-alpha "synergistically stimulated the cytotoxic activity against NK-sensitive target cells" in HIV patients [21].

B-Cell and Antibody Responses

Ta1 enhances B-cell differentiation and antibody production, which underlies its utility as a vaccine adjuvant [9][23]. This effect is thought to be indirect, mediated through enhanced T-helper cell function and dendritic cell antigen presentation.

3. Researched Applications

3.1 Chronic Hepatitis B

Hepatitis B has been the most extensively studied indication for thymosin alpha-1, with multiple randomized controlled trials conducted since 1991.

Mutchnick et al. (1991) conducted the first placebo-controlled pilot trial in 12 chronic HBV patients. The thymosin-treated group showed 86% HBV DNA clearance from serum versus 20% for placebo (p<0.04), with improvements in aminotransferases, lymphocyte counts, and interferon-gamma production persisting through 26 months of follow-up [2].

Chien et al. (1998) performed a larger RCT comparing 26-week treatment, 52-week treatment, and observation. At 18 months, complete virological response rates were 40.6% (26-week course), 26.5% (52-week course), and 9.4% (controls). The 26-week course was significantly superior (p=0.004), establishing the standard 6-month treatment duration [3].

Mutchnick et al. (1999) conducted the pivotal phase III multicenter, double-blind, placebo-controlled trial in 97 HBeAg-positive patients. Complete response was 14% (Ta1) vs. 4% (placebo), and sustained HBV DNA loss was 25% vs. 13%, showing a consistent trend favoring treatment that did not reach conventional statistical significance (p=0.084) [4].

Meta-analyses comparing Ta1 with interferon-alpha have generally shown comparable efficacy with a significantly better tolerability profile. Yang et al. (2008, PMID: 18078676) published a meta-analysis confirming this equivalence.

3.2 Chronic Hepatitis C

Ta1 has been investigated as an adjunct to interferon-based therapies for hepatitis C. Andreone et al. (1996, PMID: 8873009) conducted early pilot work. Sherman (2010) reviewed the evidence, concluding that while extensive literature supported a possible role in difficult-to-treat populations, clinical trials had not yet conclusively established benefit in combination with interferon-based regimens [5]. The advent of direct-acting antiviral agents has largely superseded immunomodulatory approaches to HCV treatment.

3.3 HIV/AIDS

Garaci et al. (1994) demonstrated that triple therapy (zidovudine + Ta1 + interferon-alpha) produced substantial increases in CD4+ T-cell numbers and function compared to zidovudine monotherapy in patients with CD4 counts of 200-500/mm3 over 12 months. The combination synergistically stimulated NK cytotoxic activity [21].

Chadwick et al. (2003) conducted a phase II trial in 20 HIV patients on HAART with persistently low CD4 counts (<200). Treatment with 3.2 mg Ta1 SC twice weekly for 12 weeks produced significantly increased sjTREC levels (a marker of new thymic T-cell output) compared to controls, suggesting enhanced thymic immune reconstitution even in heavily immunosuppressed patients [22].

Matteucci et al. (2017) reviewed the accumulated evidence, noting Ta1's unique ability to address the incomplete immune reconstitution frequently seen under HAART, including persistent inflammation and impaired cytotoxic T-cell responses [25].

3.4 Cancer Immunotherapy

Melanoma: Maio et al. (2010) conducted the largest RCT, randomizing 488 patients with metastatic melanoma to five treatment arms. Ta1 groups showed median OS of 9.4 months vs. 6.6 months for controls (HR 0.80, p=0.08), with no additional toxicity. Dose-response was explored at 1.6, 3.2, and 6.4 mg [5]. Danielli et al. (2018) followed these patients long-term and found that those who subsequently received anti-CTLA-4 therapy (ipilimumab) after Ta1 pretreatment had dramatically superior median OS of 57.8 months vs. 7.4 months without prior Ta1, suggesting synergy with immune checkpoint inhibitors [17].

Non-Small Cell Lung Cancer: The GASTO-1043 trial (Liu et al., 2022) demonstrated that weekly Ta1 during concurrent chemoradiotherapy reduced grade >=2 radiation pneumonitis from 53.6% to 36.2% (p=0.040) and grade 3-4 lymphopenia from 62.1% to 19.1% (p<0.001) [18]. Earlier work by Schulof et al. (1985) showed restoration of T-cell function after mediastinal irradiation [17].

Hepatocellular Carcinoma: Linye et al. (2021) found that postoperative Ta1 therapy in 468 HBV-related HCC patients significantly improved recurrence-free survival (HR 0.381, p<0.001) and overall survival (HR 0.308, p<0.001) over a 60-month follow-up [19].

Esophageal Cancer: Du et al. (2018) combined SBRT with Ta1 in 31 heavily pretreated metastatic esophageal SCC patients, observing a 45.2% disease control rate with evidence of abscopal immune responses and increased CD8+ T cells in responders [20].

General Cancer Adjunct: Garaci et al. (2000) reviewed evidence that combined Ta1 + low-dose interferon or IL-2 is "highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs" while reducing overall toxicity [27]. Bepler (1994) noted that Ta1 binds to VIP receptors and inhibits in vitro growth of NSCLC cell lines [29].

3.5 Sepsis and Critical Care

ETASS Trial (Wu et al., 2013): This multicenter RCT of 361 severe sepsis patients found 28-day mortality of 26.0% with Ta1 vs. 35.0% with standard care (RR 0.74, 95% CI 0.54-1.02, p=0.049 by log-rank). Significant improvements in monocyte HLA-DR expression were observed at days 3 and 7, indicating immune restoration. No serious drug-related adverse events were recorded [6].

TESTS Trial (Wu et al., 2025): The definitive phase 3 trial enrolled 1,106 sepsis patients across 22 centers. The result was negative: 28-day mortality was 23.4% (Ta1) vs. 24.1% (placebo), HR 0.99 (p=0.93). Subgroup analyses suggested potential differential effects based on age and diabetes status, with potential benefit in patients with diabetes [7].

2025 Sepsis Meta-Analysis: A systematic review and meta-analysis of all randomized controlled trials evaluating Ta1 for sepsis was published in Frontiers in Cellular and Infection Microbiology (2025), providing an updated aggregate analysis of the evidence including the TESTS trial [32]. The meta-analysis suggested that while overall mortality benefit remains uncertain for unselected sepsis populations, there may be benefit in specific subgroups with severe immunosuppression.

2025 Expert Consensus: The National Clinical Research Center for Infectious Diseases (China) and collaborating institutions published an expert consensus on the clinical application of thymosin alpha-1 in 2025 [31]. The consensus assessed quality levels of current evidence and formulated 10 recommendations spanning liver diseases, viral infections, bacterial infections, and critical illness, providing a clinical framework for Ta1 use in approved markets.

Pancreatitis: Wang et al. (2011, PMID: 20549321) showed reduced infection rates with Ta1 in severe acute pancreatitis. However, the larger trial by Ke et al. (2022) in 508 patients found no significant reduction in infected pancreatic necrosis (15.7% vs. 18.1%, p=0.48) [26].

3.6 COVID-19

Ta1 was widely investigated during the COVID-19 pandemic:

Wu et al. (2020) found that Ta1 significantly reduced 28-day mortality in critical COVID-19 patients (HR 0.11, 95% CI 0.02-0.63) in a retrospective cohort of 334 patients, with greatest benefit in patients >64 years with severe immunosuppression [8].

Shehadeh et al. (2023) conducted a prospective randomized trial in 49 patients showing that Ta1-treated patients had 3.84 times more CD4+ T cells by day 5 vs. day 1 compared to controls (p=0.01). All SAEs were deemed unrelated to treatment [25].

Other COVID-19 studies showed mixed results. Some retrospective analyses (Liu T et al., 2022, PMID: 33896653) found no mortality benefit. The overall evidence suggests that Ta1 may benefit specific subpopulations, particularly those with severe lymphopenia and immunosuppression, rather than all COVID-19 patients.

3.7 Vaccine Adjuvant

Ta1 has been studied as a vaccine adjuvant to enhance immune responses in immunocompromised populations:

Gravenstein et al. (1989) demonstrated augmented influenza antibody responses in 90 elderly men (ages 65-99) receiving Ta1 alongside trivalent influenza vaccine [9].

Carraro et al. (2012) showed that Ta1 (3.2-6.4 mg) enhanced seroconversion to pandemic H1N1 vaccine in hemodialysis patients, with the combination groups fully meeting regulatory licensing criteria by day 21 while the vaccine-only group did not (p<0.01) [23].

Tuthill et al. (2012) reviewed the vaccine adjuvant evidence, confirming consistent enhancement of vaccination responses in elderly and immunocompromised populations [22].

4. Clinical Evidence Summary

5. Dosing in Research

Dosing protocols used in published clinical studies are summarized below. These reflect research protocols and approved regimens in countries where Ta1 is authorized.

6. Pharmacokinetics

Subcutaneous Administration

Thymosin alpha-1 pharmacokinetics after subcutaneous injection have been characterized in healthy volunteers and patient populations:

• Absorption: Rapidly absorbed from the SC injection site with near-complete bioavailability
• Tmax: 2-6 hours after SC injection of 1.6 mg (the standard clinical dose)
• Cmax: Peak plasma concentrations reach approximately 20-100 ng/mL after 1.6 mg SC, depending on assay methodology
• Volume of distribution (Vd): Approximately 5-8 L, consistent with distribution into extracellular fluid space
• Protein binding: Low to moderate; Ta1 is a small, highly acidic peptide (pI approximately 4.2) that does not extensively bind plasma proteins
• Elimination half-life: Approximately 2 hours after SC administration
• Metabolism: Proteolytically degraded by tissue and circulating aminopeptidases. The acetylated N-terminus provides partial protection against aminopeptidase degradation, contributing to the peptide's usable half-life.
• Elimination: Primarily through proteolytic degradation to amino acid fragments; renal clearance of intact peptide is minimal
• Dose proportionality: Pharmacokinetics are approximately linear across the studied dose range (0.8-6.4 mg SC)
• Accumulation: No significant accumulation with twice-weekly dosing (the standard regimen), consistent with the 2-hour half-life and 72-96 hour dosing intervals

Endogenous Ta1 Levels

• Normal serum concentrations: 0.1-1.0 ng/mL in healthy adults
• Age-related decline: Serum Ta1 levels decrease progressively after thymic involution (beginning in puberty), with levels approximately 50% lower in individuals over 60 years compared to young adults
• Disease-related changes: Depressed levels in chronic hepatitis B, HIV, and advanced malignancies; elevated during acute infection as part of innate immune activation

7. Dose-Response Relationships

Hepatitis B (Virological Response)

Clinical trials have explored dose-response relationships for Ta1 in chronic hepatitis B:

• 1.6 mg SC twice weekly (26 weeks): Complete virological response rate of 40.6% at 18 months (Chien et al.) [3]
• 1.6 mg SC twice weekly (52 weeks): Response rate of 26.5%, paradoxically lower than the 26-week course, suggesting that prolonged treatment may not improve and could potentially diminish response, possibly through immune tolerance [3]
• Observation control: 9.4% spontaneous response at 18 months [3]
• Therapeutic window: The 26-week treatment duration appears optimal, suggesting that the immune-priming effect of Ta1 requires a defined treatment period followed by unassisted immune consolidation

Melanoma (Dose-Response Exploration)

The Maio et al. (2010) five-arm melanoma trial is the most informative dose-response study [5]:

• 1.6 mg Ta1: Explored in combination with DTIC +/- IFN-alpha
• 3.2 mg Ta1: Higher dose arm
• 6.4 mg Ta1: Highest dose tested
• Median OS (all Ta1 groups pooled): 9.4 months vs. 6.6 months (control), HR 0.80 (p=0.08) [5]
• No dose-limiting toxicities were observed at any dose level, and no clear dose-response relationship for OS was identified, though the trial was not adequately powered for individual dose-group comparisons

Sepsis (Standard vs. Intensive Dosing)

• ETASS trial (1.6 mg SC, protocol-defined): 28-day mortality 26.0% vs. 35.0% (p=0.049 by log-rank) [6]
• COVID-19 critical patients (1.6 mg qd or q12h): HR 0.11 for mortality in critically ill patients, with more intensive dosing (q12h) appearing to benefit the most severely immunosuppressed patients [8]
• TESTS phase 3 (1.6 mg, 1106 patients): No benefit (23.4% vs. 24.1%, p=0.93), suggesting the broader sepsis population may not benefit from standard dosing [7]

Vaccine Adjuvant (Dose-Response)

• 900 mcg/m2 twice weekly x 8 doses: Enhanced influenza antibody response in elderly (Gravenstein 1989) [9]
• 3.2 mg: Enhanced H1N1 seroconversion in hemodialysis patients [23]
• 6.4 mg: Further enhanced response vs. 3.2 mg in hemodialysis patients (p less than 0.01 for both vs. vaccine alone) [23]

8. Comparative Effectiveness

Ta1 vs. Interferon-Alpha for Chronic Hepatitis B

This is the most clinically relevant comparison, as both agents have been used for HBV treatment:

• Efficacy (virological response): Meta-analyses demonstrate comparable sustained virological response rates (approximately 25-40% for Ta1 vs. 25-37% for IFN-alpha at 12-18 months follow-up). Yang et al. (2008, PMID 18078676) confirmed non-inferiority of Ta1 monotherapy to IFN-alpha.
• Combination benefit: Lim et al. (2006) showed that Ta1 + IFN-alpha achieved HBeAg loss of 45.8% vs. 28.0% for IFN-alpha alone (p=0.067), trending toward additive benefit [study from PMID 16640105]
• Safety advantage of Ta1: The tolerability difference is dramatic. IFN-alpha causes flu-like symptoms in more than 50% of patients, depression in 10-40%, neutropenia in 20-40%, and dose-limiting fatigue requiring dose reduction in 20-30%. Ta1 causes only mild injection site reactions (less than 5%) and rare flu-like symptoms (less than 2%), with no dose-limiting toxicity ever reported [16][28].
• Current clinical context: Both agents have been largely superseded by direct-acting nucleos(t)ide analogs (tenofovir, entecavir) for first-line HBV therapy in most settings. Ta1 retains a niche in combination approaches and in patients intolerant of or unresponsive to standard antivirals.

Ta1 vs. Checkpoint Inhibitors (Cancer Immunotherapy)

The relationship between Ta1 and checkpoint inhibitors is emerging as complementary rather than competitive:

• Sequential therapy evidence: Danielli et al. (2018) reported that melanoma patients who received Ta1 followed by anti-CTLA-4 (ipilimumab) had median OS of 57.8 months vs. 7.4 months for those who received anti-CTLA-4 without prior Ta1 [17]. This dramatic difference (though from a small retrospective cohort) suggests immune preconditioning.
• Mechanistic rationale: Ta1 enhances antigen presentation (DC maturation, MHC upregulation), T-cell priming, and effector function, which could amplify the T-cell responses subsequently unleashed by checkpoint blockade. Ta1's TLR-mediated immune activation creates an immunologically "hot" tumor microenvironment more susceptible to checkpoint inhibitor therapy.
• Safety complementarity: Ta1 does not cause immune-related adverse events (irAEs), unlike checkpoint inhibitors which produce grade 3-4 irAEs in 15-40% of patients. Adding Ta1 to checkpoint regimens has not increased toxicity in the limited data available [5][17].
• Ongoing investigation: Ta1 + PD-1/PD-L1 inhibitor combinations are under investigation in Chinese clinical trials for NSCLC and HCC.

Ta1 vs. Thymosin Beta-4 (TB-500)

These thymic peptides have fundamentally different mechanisms and applications (see Section 8 comparison table). Ta1 is an immune modulator acting through TLR signaling; TB-500 is a tissue repair peptide acting through actin sequestration and cell migration. They are not interchangeable.

9. Safety and Side Effects

Thymosin alpha-1 has one of the most favorable safety profiles of any immunomodulatory agent studied in clinical trials. The 2024 comprehensive review by Dinetz et al. evaluated over 11,000 subjects across more than 30 clinical trials and concluded Ta1 is "a well-tolerated and effective immune modulator" [28].

Quantitative Safety Data Across Major Trials

| Trial | N | Drug-Related SAEs | Discontinuation Rate | Key Safety Finding | |---|---|---|---|---| | Phase III HBV (Mutchnick 1999) [4] | 97 | 0 | Less than 2% | No significant AEs vs. placebo | | ETASS Sepsis (Wu 2013) [6] | 361 | 0 | Not reported | "No serious drug-related adverse event" | | TESTS Sepsis Phase 3 (Wu 2025) [7] | 1,106 | No difference vs. placebo | Similar between arms | "No secondary or safety outcome differed significantly" | | Melanoma 5-arm (Maio 2010) [5] | 488 | No additional toxicity | Similar across arms | No increased toxicity even at 6.4 mg | | GASTO-1043 NSCLC (Liu 2022) [18] | 138 | Not increased | Similar | Grade 3-4 lymphopenia REDUCED (19.1% vs. 62.1%) | | Pancreatitis (Ke 2022) [26] | 508 | No difference | Similar | No safety concerns | | COVID-19 pilot (Shehadeh 2023) [25] | 49 | 9 SAEs, all unrelated to Ta1 | Low | No drug-attributed SAEs | | Pooled across all trials [28] | More than 11,000 | Essentially zero drug-related | Less than 5% overall | "Virtually devoid of toxicity" [16] |

Quantitative Adverse Event Rates

• Injection site reactions: Less than 5% of patients; redness, mild discomfort, typically resolving within 24 hours
• Flu-like symptoms: Less than 2% of patients; mild and transient
• Fever: Less than 1% (and often indistinguishable from underlying disease)
• Headache: Less than 1%
• Nausea: Less than 1%
• Serious adverse events causally attributed to Ta1: Zero across all published trials involving more than 11,000 subjects
• Dose-limiting toxicities: None identified at any dose tested (up to 6.4 mg SC) [5]
• Laboratory abnormalities: No significant hepatic, renal, or hematologic abnormalities attributed to Ta1
• Immune-related adverse events (irAEs): None reported, in contrast to checkpoint inhibitors which produce grade 3-4 irAEs in 15-40% of patients
• Drug interactions: No clinically significant drug interactions identified; safely combined with interferon-alpha, dacarbazine, chemotherapy, radiation, antiretrovirals, and standard ICU medications

Safety Comparison with Interferon-Alpha

This comparison is clinically relevant as both are used for hepatitis B:

| Adverse Event | Ta1 Incidence | IFN-alpha Incidence | |---|---|---| | Flu-like symptoms | Less than 2% | More than 50% | | Depression | Not reported | 10-40% | | Neutropenia | Not reported | 20-40% | | Dose-limiting fatigue | Not reported | 20-30% | | Injection site reaction | Less than 5% | 15-30% | | Dose reduction required | 0% | 20-40% | | Treatment discontinuation for AEs | Less than 2% | 10-20% |

Camerini and Garaci (2015) characterized the safety profile as "excellent" and the peptide as "virtually devoid of toxicity" [16]. This remarkable tolerability is likely related to Ta1 being an endogenous human peptide administered at near-physiological concentrations.

10. Regulatory Status

• Approved in 35+ countries under the trade name Zadaxin (manufactured originally by SciClone Pharmaceuticals, later acquired by entities operating primarily in China): approved indications include chronic hepatitis B, hepatitis C, and use as an immunomodulatory agent
• China: Major market; approved for hepatitis B and as immune enhancer; widely used in oncology and critical care settings
• Italy and Europe: Used in clinical practice and clinical trials; not EMA-centrally approved
• United States: Not FDA approved. Was under clinical development for hepatitis C and melanoma. In 2023, the FDA added restrictions affecting its availability through compounding pharmacies [28]
• Other markets: Approved in countries across Asia (South Korea, Philippines, India, Singapore), the Middle East, and Latin America

11. Comparison with Thymosin Beta-4

Thymosin alpha-1 and thymosin beta-4 (TB-500) are both derived from the thymus gland but are fundamentally different peptides with distinct biology:

| Feature | Thymosin Alpha-1 | Thymosin Beta-4 | |---------|-----------------|-----------------| | Size | 28 amino acids | 43 amino acids | | Molecular weight | ~3,108 Da | ~4,964 Da | | Precursor | Prothymosin alpha (nuclear) | Direct gene product (cytoplasmic) | | Primary function | Immunomodulation | Actin sequestration / tissue repair | | Cellular distribution | Primarily thymic epithelial cells | Nearly all nucleated cells | | Mechanism | TLR signaling, DC/T-cell modulation | Actin binding, cell migration | | Clinical status | Approved in 35+ countries | Orphan drug designation only | | Key applications | Hepatitis B/C, cancer, sepsis | Wound healing, cardiac repair, corneal healing |

Yao et al. (2007) directly compared the two peptides and found that Ta1 significantly upregulated DC activation markers while thymosin beta-4 (Tbeta4) and thymosin beta-10 (Tbeta10) "showed no comparable effects" on dendritic cell maturation [10].

12. Historical Context

• 1961: Jacques Miller demonstrates the immunological importance of the thymus gland
• 1966: Allan L. Goldstein begins isolating thymic peptides at the Albert Einstein College of Medicine
• 1972: Goldstein and colleagues identify "thymosin fraction 5," a partially purified thymic extract with immune-restoring activity
• 1977: Thymosin alpha-1 is isolated, sequenced, and chemically synthesized — the first individual thymic peptide available for study [1]
• 1980s: Early clinical trials begin in primary immunodeficiencies (DiGeorge syndrome) under physician-sponsored INDs, and in lung cancer [14]
• 1991: First placebo-controlled trial in hepatitis B by Mutchnick et al. [2]
• 1996: SciClone Pharmaceuticals begins large-scale clinical development
• 1998: Chien et al. establish efficacy and optimal 26-week dosing in hepatitis B [3]
• 1999: Zadaxin receives first regulatory approvals internationally
• 2000s: Expansion into cancer immunotherapy, sepsis, and vaccine adjuvant research
• 2009: Approved in over 35 countries [15]
• 2010: Landmark melanoma trial (488 patients) and comprehensive reviews published [5][14]
• 2020-2022: Rapid deployment in COVID-19 clinical studies across multiple countries [8][24][25]
• 2025: TESTS phase 3 sepsis trial (1,106 patients) published in BMJ -- negative result for primary endpoint [7]. Expert consensus on clinical application of Ta1 published by the National Clinical Research Center for Infectious Diseases (China), forming 10 recommendations across liver diseases, viral infections, bacterial infections, and critical illness [31]. A systematic review and meta-analysis of all sepsis RCTs re-evaluated the aggregate evidence [32]. New clinical trial (NCT06821100) initiated evaluating thymalfasin as vaccine response enhancer.

13. Related Peptides

See also: TB-500 (Thymosin Beta-4)

14. References

1. [1] Goldstein AL, Low TL, McAdoo M, et al. (1977). Thymosin alpha-1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences. PubMed
2. [2] Mutchnick MG, Appelman HD, Chung HT, et al. (1991). Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. PubMed
3. [3] Chien RN, Liaw YF, Chen TC, et al. (1998). Efficacy of thymosin alpha-1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. PubMed
4. [4] Mutchnick MG, Lindsay KL, Schiff ER, et al. (1999). Thymosin alpha-1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Journal of Viral Hepatitis. PubMed
5. [5] Maio M, Mackiewicz A, Testori A, et al. (2010). Large randomized study of thymosin alpha-1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology. PubMed
6. [6] Wu J, Zhou L, Liu J, et al. (2013). The efficacy of thymosin alpha-1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care. PubMed
7. [7] Wu J, Pei F, Zhou L, et al. (2025). The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. PubMed
8. [8] Wu M, Ji JJ, Zhong L, et al. (2020). Thymosin alpha-1 therapy in critically ill patients with COVID-19: a multicenter retrospective cohort study. International Immunopharmacology. PubMed
9. [9] Gravenstein S, Duthie EH, Miller BA, et al. (1989). Augmentation of influenza antibody response in elderly men by thymosin alpha-1. Journal of the American Geriatrics Society. PubMed
10. [10] Yao Q, Doan LX, Zhang R, et al. (2007). Thymosin-alpha-1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. Immunology Letters. PubMed
11. [11] Giacomini E, Severa M, Rizzo F, et al. (2015). Dual effect of thymosin alpha-1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists. Expert Opinion on Biological Therapy. PubMed
12. [12] Tao N, Xu X, Ying Y, et al. (2023). Thymosin alpha-1 and its role in viral infectious diseases: the mechanism and clinical application. Molecules. PubMed
13. [13] King R, Tuthill C (2016). Immune modulation with thymosin alpha-1 treatment. Vitamins and Hormones. PubMed
14. [14] Tuthill C, Rios I, McBeath R (2010). Thymosin alpha-1: past clinical experience and future promise. Annals of the New York Academy of Sciences. PubMed
15. [15] Goldstein AL (2009). From lab to bedside: emerging clinical applications of thymosin alpha-1. Expert Opinion on Biological Therapy. PubMed
16. [16] Camerini R, Garaci E (2015). Historical review of thymosin alpha-1 in infectious diseases. Expert Opinion on Biological Therapy. PubMed
17. [17] Danielli R, Fonsatti E, Pezzani L, et al. (2018). Long-term follow up of metastatic melanoma patients treated with thymosin alpha-1: investigating immune checkpoints synergy. Expert Opinion on Biological Therapy. PubMed
18. [18] Liu F, Wu Y, Long J, et al. (2022). Efficacy of thymosin alpha-1 in management of radiation pneumonitis in patients with locally advanced NSCLC treated with concurrent chemoradiotherapy (GASTO-1043). International Journal of Radiation Oncology, Biology, Physics. PubMed
19. [19] Linye H, et al. (2021). Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma. Medicine. PubMed
20. [20] Du D, Song T, Dai H, et al. (2018). Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients. Oncoimmunology. PubMed
21. [21] Garaci E, Pica F, Sinibaldi-Vallebona P, et al. (1994). Combination treatment with zidovudine, thymosin alpha-1 and interferon-alpha in human immunodeficiency virus infection. International Journal of Clinical and Laboratory Research. PubMed
22. [22] Chadwick D, Pido-Lopez J, Gotch F, et al. (2003). A pilot study of the safety and efficacy of thymosin alpha-1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking HAART. Clinical and Experimental Immunology. PubMed
23. [23] Carraro G, Naso A, Montomoli E, et al. (2012). Thymosin-alpha-1 (Zadaxin) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine. PubMed
24. [24] Dominari A, Hathaway D, Pandav K, et al. (2020). Thymosin alpha-1: a comprehensive review of the literature. World Journal of Virology. PubMed
25. [25] Shehadeh F, Benitez G, Gakis G, et al. (2023). A pilot trial of thymalfasin (thymosin-alpha-1) for the treatment of COVID-19. Journal of Infectious Diseases. PubMed
26. [26] Ke L, Zhou J, Mao W, et al. (2022). Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Medicine. PubMed
27. [27] Garaci E, Pica F, Rasi G, Favalli C (2000). Thymosin alpha-1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopharmacology. PubMed
28. [28] Dinetz E, et al. (2024). Comprehensive review of the safety and efficacy of thymosin alpha-1. Alternative Therapies in Health and Medicine. PubMed
29. [29] Bepler G (1994). Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review. Cancer Investigation. PubMed
30. [30] Mao L (2023). Thymosin alpha-1 - Reimagine its broader applications in the immuno-oncology era. International Immunopharmacology. PubMed
31. [31] National Clinical Research Center for Infectious Diseases, et al. (2025). Expert Consensus on the Clinical Application of Thymosin Alpha-1. Infectious Microbes and Diseases.
32. [32] Various authors. (2025). Efficacy of thymosin alpha-1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology.